Ceria Therapeutics is pioneering innovative drug products aimed at addressing inflammatory disorders through a unique platform for micro-RNA delivery. Their primary focus is on the use of cerium oxide nanoparticles conjugated with micro-Ribonucleic Acid (miRNA), specifically miRNA-146a, which plays a critical role in regulating the inflammatory response. The company has identified a link between reduced levels of miRNA-146a and non-healing wounds, particularly in diabetic foot ulcers. By replenishing this molecule at the site of inflammation, Ceria Therapeutics aims to restore the body's natural healing processes, thereby transforming the treatment landscape for various conditions, including Acute Respiratory Distress Syndrome (ARDS), Inflammatory Bowel Disease (IBD), and non-healing wounds.

The therapeutic approach of Ceria Therapeutics involves utilizing CNP-miR146a, where the miRNA component effectively blocks key genes involved in the inflammatory cascade, while the cerium oxide nanoparticles neutralize free radicals. This dual-action mechanism not only halts inflammation but also promotes healing by ensuring that the therapeutic agents are readily absorbed by cells at the site of infection. The company emphasizes the safety and efficacy of their products, as both miRNA-146a and cerium oxide are naturally occurring and non-toxic, minimizing the risk of side effects. Through this innovative technology, Ceria Therapeutics aims to eliminate the consequences of inflammation and improve patient outcomes across a range of inflammatory conditions.

United States

Ceria Therapeutics develops innovative drug products for inflammatory disorders. We intend to transform lives by eliminating the consequences of inflammation.

Ceria Therapeutics

Company Details